BioCentury
ARTICLE | Clinical News

Hepatitis C: Phase IIa data

June 10, 2002 7:00 AM UTC

Forty-eight week results from a previously reported placebo-controlled Belgian Phase II study in 35 patients showed the vaccine was well tolerated and that E1-specific antibodies increased with each i...